Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | ctDNA prognostic model for rPFS in mCRPC: Alliance A031201 analysis

Susan Halabi • 30 May 2026
ASCO 2026
Genitourinary Cancer Prostate Cancer
Alliance A031201

Susan Halabi, PhD, FSCT, FASA, FASCO, Duke Cancer Institute, Durham, NC, describes the development of a circulating tumour DNA (ctDNA)-based clinical-genetic prognostic model for radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC), using data from the Alliance A031201 trial (NCT01949337). Integrating genomic and clinical variables, the model robustly stratified patients into distinct risk groups, supporting its potential to inform individualized risk assessment and treatment intensification strategies in the first-line androgen receptor pathway inhibitor setting. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Susan Halabi

Prognostic model for rPFS in mCRPC incorporating ctDNA with established risk factors
1:42
Prognostic model for rPFS in mCRPC incorporating ctDNA with established risk factors
Susan Halabi • 29 May 2026
Clinical adoption of ctDNA assays into treatment decisions for mCRPC
0:46
Clinical adoption of ctDNA assays into treatment decisions for mCRPC
Susan Halabi • 29 May 2026
ctDNA models for predicting survival outcomes in mCRPC
1:32
ctDNA models for predicting survival outcomes in mCRPC
Susan Halabi • 2 Jun 2024
Targeting genetic variants in mCRPC to improve survival outcomes
1:17
Targeting genetic variants in mCRPC to improve survival outcomes
Susan Halabi • 2 Jun 2024

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals